Skip to main content
Top
Published in: Cardiology and Therapy 1/2023

Open Access 08-12-2022 | Direct Oral Anticoagulant | Original Research

Pulmonary Thromboembolism Developed During Hospitalization: A Nationwide Retrospective Observational Study Using Claims Data

Authors: Miki Imura, Tsunehisa Yamamoto, Ken-Ichi Hiasa

Published in: Cardiology and Therapy | Issue 1/2023

Login to get access

Abstract

Introduction

Evidence regarding the development of pulmonary thromboembolism (PE) during hospitalization is unclear. We hypothesized that the incidence of PE could vary depending on clinical department and aimed to conduct a survey on the incidence of in-hospital PE.

Methods

We conducted a retrospective analysis using claims data of in-hospital patients in Japan. We collected background information regarding patients with and without PE occurrence during hospitalization. Further, we determined the incidence of PE and implemented prophylactic procedures in patients with and without surgery according to clinical department at admission. Finally, we examined the duration of hospital stay and in-hospital mortality rates in patients with and without PE.

Results

We found that 5007 (0.107%, 20.61 per 1000 person-years) patients developed PE during hospitalization and differed by clinical department at admission. Moreover, 2272 (0.095%, 19.3 per 1000 person-years) and 2735 (0.119%, 21.8 per 1000 person-years) patients with and without surgery, respectively, developed PE during hospitalization (P < 0.001). Further, 33.8% of inpatients underwent prophylactic procedures for PE; however, the implementation rate differed between patients with and without surgery (59.2% vs. 7.3%, P < 0.001). The median duration of hospital stay in patients with and without PE was 31.0 and 11.0 days, and the in-hospital mortality rates in patients with and without PE were 11.0% and 3.5%, respectively (P < 0.001).

Discussion

The incidence of in-hospital PE differed according to patient characteristics, clinical departments, and presence/absence of surgery. The onset of PE during hospitalization leads to prolonged hospital stay and in-hospital death.

Conclusion

It is important to conduct a proper risk assessment on admission as well as to implement proper prophylactic procedures to prevent the development of PE during hospitalization.
Appendix
Available only for authorised users
Literature
3.
go back to reference Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021. Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021.
4.
5.
go back to reference Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609. Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609.
6.
go back to reference Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol. 2001;24:132–8.CrossRefPubMed Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol. 2001;24:132–8.CrossRefPubMed
7.
go back to reference Ota M, Nakamura M, Yamada N, et al. Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels. 2002;17:7–11.CrossRefPubMed Ota M, Nakamura M, Yamada N, et al. Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels. 2002;17:7–11.CrossRefPubMed
9.
go back to reference Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S–e226S.CrossRefPubMedPubMedCentral Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S–e226S.CrossRefPubMedPubMedCentral
10.
go back to reference Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism–international consensus statement. Int Angiol. 2013;32:111–260.PubMed Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism–international consensus statement. Int Angiol. 2013;32:111–260.PubMed
11.
go back to reference Yamaguchi Y, Fuji T, Akagi M, et al. The epidemiological study of venous thromboembolism and bleeding events using a Japanese healthcare database—validation study. Jpn J Drug Inform. 2015;17:87–93. Yamaguchi Y, Fuji T, Akagi M, et al. The epidemiological study of venous thromboembolism and bleeding events using a Japanese healthcare database—validation study. Jpn J Drug Inform. 2015;17:87–93.
12.
go back to reference Normand SLT, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following an acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387–98.CrossRefPubMed Normand SLT, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following an acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387–98.CrossRefPubMed
13.
go back to reference Sakuma M, Nakamura M, Yamada N, et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305–9.CrossRefPubMed Sakuma M, Nakamura M, Yamada N, et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305–9.CrossRefPubMed
14.
go back to reference Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.CrossRefPubMed Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.CrossRefPubMed
15.
go back to reference Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.
17.
go back to reference Ohashi Y, Ikeda M, Kunitoh H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020;50:1246–53.CrossRefPubMedPubMedCentral Ohashi Y, Ikeda M, Kunitoh H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020;50:1246–53.CrossRefPubMedPubMedCentral
18.
go back to reference Tsubata Y, Hotta T, Hamai K, et al. Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study). Ther Adv Med Oncol. 2022;14:175883592211101.CrossRef Tsubata Y, Hotta T, Hamai K, et al. Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study). Ther Adv Med Oncol. 2022;14:175883592211101.CrossRef
19.
go back to reference Connolly GC, Francis CW. Cancer-associated thrombosis. Hematol Am Soc Hematol Educ Program. 2013;2013:684–91.CrossRef Connolly GC, Francis CW. Cancer-associated thrombosis. Hematol Am Soc Hematol Educ Program. 2013;2013:684–91.CrossRef
20.
21.
go back to reference Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3:3898–944.CrossRefPubMedPubMedCentral Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3:3898–944.CrossRefPubMedPubMedCentral
22.
go back to reference Morrow M, Lynch-Smith D. Factor V Leiden: development of VTE in surgery and trauma patients: a systematic review. Dimens Crit Care Nurs. 2022;41:190–9.CrossRefPubMed Morrow M, Lynch-Smith D. Factor V Leiden: development of VTE in surgery and trauma patients: a systematic review. Dimens Crit Care Nurs. 2022;41:190–9.CrossRefPubMed
23.
go back to reference Sakon M, Maehara Y, Yoshikawa H, et al. Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006;4:581–6.CrossRefPubMed Sakon M, Maehara Y, Yoshikawa H, et al. Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006;4:581–6.CrossRefPubMed
24.
go back to reference Fuji T, Akagi M, Abe Y, et al. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database. J Orthop Surg Res. 2017;12:55.CrossRefPubMedPubMedCentral Fuji T, Akagi M, Abe Y, et al. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database. J Orthop Surg Res. 2017;12:55.CrossRefPubMedPubMedCentral
25.
go back to reference Aggarwal A, Rickles FR. Global public awareness of venous thromboembolism: comment. J Thromb Haemost. 2016;14:1110–1.CrossRefPubMed Aggarwal A, Rickles FR. Global public awareness of venous thromboembolism: comment. J Thromb Haemost. 2016;14:1110–1.CrossRefPubMed
26.
27.
go back to reference Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? JAMA. 2006;295:199–207.CrossRefPubMed Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? JAMA. 2006;295:199–207.CrossRefPubMed
28.
go back to reference Scicchitano P, Tucci M, Bellino MC, et al. The impairment in kidney function in the oral anticoagulation era. A pathophysiological insight. Cardiovasc Drugs Ther. 2021;35:505–19.CrossRefPubMed Scicchitano P, Tucci M, Bellino MC, et al. The impairment in kidney function in the oral anticoagulation era. A pathophysiological insight. Cardiovasc Drugs Ther. 2021;35:505–19.CrossRefPubMed
29.
go back to reference Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Eng J Med. 2013;369:799–808.CrossRef Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Eng J Med. 2013;369:799–808.CrossRef
30.
go back to reference Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Eng J Med. 2013;369:1406–15.CrossRef Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Eng J Med. 2013;369:1406–15.CrossRef
31.
go back to reference Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J Med. 2010;363:2499–510.CrossRef Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J Med. 2010;363:2499–510.CrossRef
32.
go back to reference Cortese F, Scicchitano P, Gesualdo M, et al. Apixaban: effective and safe in preventing thromboembolic events in patients with atrial fibrillation and renal failure. Curr Med Chem. 2017;24:3813–27.CrossRefPubMed Cortese F, Scicchitano P, Gesualdo M, et al. Apixaban: effective and safe in preventing thromboembolic events in patients with atrial fibrillation and renal failure. Curr Med Chem. 2017;24:3813–27.CrossRefPubMed
Metadata
Title
Pulmonary Thromboembolism Developed During Hospitalization: A Nationwide Retrospective Observational Study Using Claims Data
Authors
Miki Imura
Tsunehisa Yamamoto
Ken-Ichi Hiasa
Publication date
08-12-2022
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2023
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-022-00290-6

Other articles of this Issue 1/2023

Cardiology and Therapy 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine